Singapore markets closed

Evotec SE (EVT.DE)

XETRA - XETRA Delayed Price. Currency in EUR
Add to watchlist
14.47+0.10 (+0.66%)
At close: 05:35PM CET
Full screen
Previous close14.38
Open14.38
Bid14.48 x 105300
Ask14.50 x 169300
Day's range14.18 - 14.77
52-week range12.61 - 24.44
Volume796,897
Avg. volume873,614
Market cap2.564B
Beta (5Y monthly)1.09
PE ratio (TTM)N/A
EPS (TTM)-0.53
Earnings date24 Apr 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est27.00
  • Simply Wall St.

    Evotec (ETR:EVT shareholders incur further losses as stock declines 3.7% this week, taking three-year losses to 59%

    Investing in stocks inevitably means buying into some companies that perform poorly. But the long term shareholders of...

  • Reuters

    UPDATE 1-Evotec says it promptly reported share trades withheld by former CEO

    German biotech firm Evotec on Monday said it had immediately reported trades in its shares by its former CEO as soon as it was informed of the transactions that he had kept under wraps for up to three years. "Evotec has acted always in compliance with the statutory regulations and our own very strict compliance code," supervisory board Chair Iris Loew Friedrich said in an analyst call. Evotec, which works in drug development with partners including Novo Nordisk, Bayer and Bristol-Myers Squibb, said on Jan. 3 that CEO Werner Lanthaler would resign for personal reasons after almost 15 years with the company.

  • Reuters

    Evotec says it promptly reported share trades withheld by former CEO

    FRANKFURT (Reuters) -German biotech firm Evotec on Monday said it had immediately reported trades in its shares by its former CEO as soon as it was informed of the transactions that he had kept under wraps for up to three years. "Evotec has acted always in compliance with the statutory regulations and our own very strict compliance code," supervisory board Chair Iris Loew Friedrich said in an analyst call. Evotec, which works in drug development with partners including Novo Nordisk, Bayer and Bristol-Myers Squibb , said on Jan. 3 that CEO Werner Lanthaler would resign for personal reasons after almost 15 years with the company.